How GLP-1 Medications Work: A 2026 Research Overview

Page updated 16 October 2026

By TotalHealthRD.com Nutrition Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content is provided by TotalHealthRD.com, a health information website operated by a Registered Dietitian Nutritionist — not a medical practice or healthcare facility. GLP-1 medications are prescription-only products requiring evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved finished drug products. Individual results vary. Consult your physician before starting, stopping, or changing any prescription medication.

By TotalHealthRD.com Editorial Team

Quick Answer: GLP-1 medications work by mimicking glucagon-like peptide-1, a hormone naturally released by the gut after eating. This hormone signals fullness to the brain, slows the rate of gastric emptying, and supports insulin release after meals. Semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist) are the two active ingredients prescribed in compounded GLP-1 telehealth programs. Clinical trials — the STEP trials for semaglutide and the SURMOUNT-1 trial for tirzepatide — reported average weight reductions of approximately 15% and 22.5% of body weight, respectively, in eligible populations over 68-72 weeks. These are prescription medications requiring clinician evaluation; they are not OTC supplements and cannot be self-prescribed.

Why Weight Loss Is Harder Than Calorie Math Suggests

The experience is familiar to most women navigating their 40s and 50s: the same calorie intake that maintained a stable weight at 35 begins to produce slow, steady gain. Exercise intensity increases, portions shrink, and the scale still moves in the wrong direction. That frustration isn't a failure of effort. It reflects real physiological changes — in hormonal signaling, metabolic rate, and hunger regulation — that respond to more than behavioral adjustment alone.

GLP-1 medications intervene at the hormonal level. They don't burn fat directly or suppress metabolism; they alter the signaling environment that governs hunger, fullness, and how quickly the body processes food. Understanding what they do mechanically is a useful context for anyone evaluating whether a telehealth GLP-1 program fits their health goals. For a detailed review of one telehealth program in this category, see Novi GLP-1 Review 2026.

What GLP-1 Is and Why It Matters

Glucagon-like peptide-1 is a hormone produced by L-cells in the small intestine and colon in response to food intake. Its primary roles are appetite regulation, gastric emptying control, and post-meal insulin secretion. When GLP-1 is released after a meal, it signals the hypothalamus — the brain region governing hunger — to reduce appetite. It also slows the rate at which food moves from the stomach into the small intestine, which extends the physical sensation of fullness.

In people with obesity, GLP-1 signaling can be impaired. Research published in the Journal of Clinical Endocrinology and Metabolism and elsewhere has documented blunted post-meal GLP-1 responses in individuals with higher body mass — meaning the natural signal that should slow eating fires with less intensity than in lean individuals. GLP-1 receptor agonist medications address this by providing a sustained pharmacological version of that signal, independent of food intake, at receptor-level concentrations well above what endogenous GLP-1 achieves.

The Biological Mechanism Behind GLP-1 Receptor Agonists

Semaglutide, the active ingredient in Ozempic and Wegovy and in compounded semaglutide programs, is a modified GLP-1 molecule. The modification — attachment of a fatty acid side chain — extends its half-life from the endogenous GLP-1's 1-2 minutes to approximately one week, enabling once-weekly subcutaneous injection. At therapeutic doses, semaglutide occupies GLP-1 receptors in the hypothalamus, brainstem, and peripheral tissues, producing three main effects: reduced appetite signaling, delayed gastric emptying, and improved insulin secretion in response to elevated blood glucose.

Tirzepatide adds a second receptor pathway. It is a dual GIP/GLP-1 receptor agonist — it activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another incretin hormone involved in insulin secretion and fat storage regulation. The dual mechanism appears to produce additive effects in both appetite suppression and metabolic response. Clinical data from the SURMOUNT-1 trial (New England Journal of Medicine, 2022) reported that tirzepatide at the highest tested dose achieved a mean weight reduction of approximately 22.5% of body weight over 72 weeks — somewhat greater than semaglutide outcomes reported in the STEP-1 trial (approximately 14.9% mean reduction over 68 weeks in adults without diabetes).

Both mechanisms require weekly injection and sustained use — weight regain after stopping either medication is well-documented in the clinical literature. GLP-1 pharmacotherapy is not a short-term intervention.

What the Research Shows About Weight Outcomes

The STEP trial series for semaglutide involved more than 4,500 participants without diabetes across multiple trials, with STEP-1 (NEJM 2021, Wilding et al.) showing a mean weight reduction of 14.9% over 68 weeks with 2.4mg weekly semaglutide versus 2.4% in the placebo group. STEP-4 (NEJM 2021, Rubino et al.) demonstrated that continuing semaglutide for 48 additional weeks maintained weight loss, while switching to placebo resulted in significant weight regain — reinforcing that the medication's effect persists only with continued use.

The SURMOUNT-1 trial for tirzepatide (NEJM 2022, Jastreboff et al.) randomized 2,539 adults with obesity or overweight plus a related condition. At the highest dose (15mg weekly), the mean weight reduction was 22.5% over 72 weeks versus 2.4% with placebo. Tirzepatide consistently produced numerically larger weight reductions than semaglutide in trials where both were studied, though no direct head-to-head randomized controlled trial has compared the two agents in identical populations.

An important research caveat: these trial outcomes were measured with FDA-approved formulations (Wegovy at 2.4mg, Zepbound at up to 15mg), not with compounded versions. Compounded medications have not been the subject of independent clinical trials. Whether the outcomes from FDA-approved trials apply to compounded versions prepared by different manufacturers at different quality standards is clinically uncertain — a fact the FDA's recent regulatory activity around compounded GLP-1s explicitly acknowledges.

Lifestyle Variables That Interact With GLP-1 Therapy

GLP-1 medications reduce appetite and slow gastric emptying, but they do not eliminate the need for a healthy diet or physical activity. The clinical trials that produced the weight loss data cited above were conducted alongside structured lifestyle counseling — participants received nutrition guidance and physical activity recommendations as part of the trial protocol. Outcomes in real-world settings, without that accompanying behavioral support, tend to be more variable.

Three lifestyle variables consistently interact with GLP-1 outcomes in the research literature. Protein intake matters because appetite suppression can make it easy to undereat protein, accelerating lean mass loss alongside fat loss; research suggests higher protein intake during caloric restriction preserves muscle mass more effectively. Sleep quality matters because poor sleep impairs the same hormonal pathways that GLP-1 acts on, and inadequate sleep has been associated with attenuated weight-loss responses to dietary interventions. Resistance training matters for the same lean mass preservation reason — weight lost during GLP-1 therapy includes some proportion of muscle, and resistance exercise training during the weight loss period can reduce that proportion.

For women in midlife specifically, these variables interact with perimenopausal hormonal changes that affect metabolic rate, fat distribution, and lean mass, independent of GLP-1 pharmacology.

Where GLP-1 Telehealth Programs Fit in the Weight Management Landscape

GLP-1 telehealth programs represent a pharmacological intervention — one point on a spectrum that includes dietary approaches, behavioral programs, and surgical options. They are not a replacement for clinical evaluation when significant weight-related health conditions are present; they are one tool within a broader medical framework for obesity management.

The 2023 American Obesity Association Clinical Practice Statement and related Endocrine Society guidelines support the use of GLP-1 receptor agonists in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, when lifestyle interventions alone have been insufficient. Telehealth programs that prescribe these medications operate within that framework — the prescribing clinician applies the same eligibility criteria regardless of whether the visit is virtual or in-person.

The difference between a telehealth cash-pay program and a traditional primary care referral is primarily access and cost structure. Telehealth programs like Novi may help reduce wait times for specialist appointments and offer cash-pay pricing well below brand-name retail prices. They do not change the pharmacology, the side-effect profile, or the need for appropriate clinical oversight. For a comparison of available programs, see GLP-1 Telehealth Comparison 2026: Hims, LifeMD, Novi, Ro. For individuals who have been managing weight through other supplement-based approaches, including OTC weight management supplements, the clinical evidence framework for GLP-1 medications is categorically different — see our earlier weight management supplement review for context on the supplement side of that spectrum.

When to Seek Clinical Evaluation Rather Than a Telehealth Program

Telehealth GLP-1 programs are appropriate for many adults, but several clinical situations warrant in-person evaluation with a physician before pursuing a telehealth-prescribing program. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome is an absolute contraindication to GLP-1 receptor agonists per the FDA boxed warning on approved labeling. Active or recent pancreatitis, severe gastrointestinal disease, and uncontrolled type 1 diabetes are conditions requiring in-person clinical evaluation. If you are currently taking insulin or sulfonylurea medications for diabetes management, the interaction risk between those medications and GLP-1 agonists — specifically hypoglycemia — requires physician supervision rather than asynchronous telehealth intake.

The telehealth intake process for most programs involves a questionnaire and, in some cases, a brief virtual consultation. That format is not equivalent to a physical exam, recent labs, or a comprehensive medication reconciliation review. If your clinical picture is complex — multiple comorbidities, several prescription medications, recent cardiovascular events — a face-to-face evaluation with a physician or obesity medicine specialist provides a more complete foundation before starting pharmacotherapy. The full safety and interaction picture is covered in the GLP-1 Safety Guide 2026.

Frequently Asked Questions

How long does it take for GLP-1 medications to work?

Appetite suppression effects typically begin within the first one to two weeks of starting a GLP-1 medication, though the dose at which most people start — the lowest titration dose — is not the therapeutic dose. Dose escalation takes 16 to 20 weeks in most protocols, meaning meaningful weight loss usually begins between weeks 4 and 12, with the rate increasing as the dose reaches therapeutic levels. The clinical trial weight loss outcomes cited above were measured at 68-72 weeks — they represent over a year of sustained use at therapeutic dose, not early results.

Do GLP-1 medications require a specific diet?

No specific diet is required, but dietary quality significantly affects outcomes. Protein intake in the range of 1.2-1.6g per kilogram of body weight per day is commonly recommended during GLP-1-supported weight loss to preserve lean mass. High-fat, high-calorie foods can worsen gastrointestinal side effects, particularly during dose escalation. Most telehealth programs include some level of dietary coaching or guidance; the clinical trials that established GLP-1 efficacy data all included concurrent lifestyle counseling. Eating to support lean mass and minimize side effects improves both the experience and the outcomes.

What happens when you stop GLP-1 medications?

Weight regain after stopping GLP-1 medications is well-documented and substantial. The STEP-4 trial demonstrated that participants who stopped semaglutide after 20 weeks regained two-thirds of their prior weight loss within the following 48 weeks. This does not mean the medication “failed” — it reflects that GLP-1 medications address a hormonal signal, not the underlying physiology that created the obesity. Stopping the medication removes that signal. Long-term use appears to be the clinical framework that sustains outcomes, which has both cost implications and ongoing monitoring requirements. Discuss with your prescribing physician the expected treatment duration before starting.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.